BONO, Marco
 Distribuzione geografica
Continente #
NA - Nord America 2.520
EU - Europa 1.744
AS - Asia 1.335
Continente sconosciuto - Info sul continente non disponibili 242
SA - Sud America 239
AF - Africa 46
OC - Oceania 4
Totale 6.130
Nazione #
US - Stati Uniti d'America 2.436
SG - Singapore 539
IT - Italia 532
RU - Federazione Russa 495
CN - Cina 279
DE - Germania 226
BR - Brasile 193
VN - Vietnam 136
FI - Finlandia 131
HK - Hong Kong 125
FR - Francia 83
PL - Polonia 76
GB - Regno Unito 59
IN - India 50
CA - Canada 43
JP - Giappone 41
BD - Bangladesh 34
NL - Olanda 29
SE - Svezia 23
MX - Messico 20
PK - Pakistan 16
RO - Romania 15
KR - Corea 14
TR - Turchia 14
IE - Irlanda 13
ZA - Sudafrica 13
AT - Austria 12
ES - Italia 12
IQ - Iraq 12
EC - Ecuador 9
IR - Iran 9
MY - Malesia 9
NP - Nepal 9
AR - Argentina 8
EG - Egitto 8
ID - Indonesia 8
CO - Colombia 7
JM - Giamaica 7
BE - Belgio 6
KE - Kenya 6
UA - Ucraina 6
UZ - Uzbekistan 6
CI - Costa d'Avorio 5
MA - Marocco 5
SA - Arabia Saudita 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
LT - Lituania 4
PY - Paraguay 4
UY - Uruguay 4
AU - Australia 3
AZ - Azerbaigian 3
BO - Bolivia 3
CH - Svizzera 3
CL - Cile 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
MM - Myanmar 3
PE - Perù 3
PH - Filippine 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
AL - Albania 2
CR - Costa Rica 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MO - Macao, regione amministrativa speciale della Cina 2
SN - Senegal 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
FJ - Figi 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
KY - Cayman, isole 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
OM - Oman 1
PR - Porto Rico 1
SI - Slovenia 1
SV - El Salvador 1
TH - Thailandia 1
TW - Taiwan 1
Totale 5.890
Città #
Ashburn 393
Singapore 324
San Jose 210
Chandler 155
Fairfield 147
Hong Kong 114
Palermo 114
Helsinki 109
Moscow 105
Munich 92
Council Bluffs 90
Rome 82
The Dalles 77
Woodbridge 77
Beijing 68
Houston 62
Zgierz 62
Wilmington 61
New York 57
Seattle 56
Los Angeles 47
Cambridge 40
Dallas 39
Tokyo 39
Ho Chi Minh City 38
Hefei 33
Santa Clara 33
Hanoi 32
Chicago 31
Medford 31
Ann Arbor 30
Frankfurt am Main 30
Lauterbourg 29
Des Moines 28
Boardman 27
Buffalo 25
Milan 19
São Paulo 19
Princeton 18
Orem 17
Phoenix 17
Bremen 16
Lawrence 14
London 14
Naples 14
San Diego 14
Ludwigshafen am Rhein 13
Atlanta 12
Dublin 12
Montreal 12
Seoul 12
Kitzingen 11
Lappeenranta 11
Warsaw 11
Brooklyn 10
Chennai 10
Nuremberg 10
Haiphong 9
Johannesburg 9
Kumar 8
Mumbai 8
Pune 8
San Francisco 8
Turin 8
Altamura 7
Aversa 7
Denver 7
Monza 7
Redwood City 7
Rio de Janeiro 7
Salt Lake City 7
Schiffdorf 7
Stockholm 7
Tappahannock 7
Venice 7
Baghdad 6
Bexley 6
Boston 6
Brussels 6
Cairo 6
Jinan 6
Kuala Lumpur 6
Manchester 6
Messina 6
Paris 6
Querétaro 6
Toronto 6
Abidjan 5
Bari 5
Cagliari 5
Da Nang 5
Falkenstein 5
Mexico City 5
Redondo Beach 5
Tashkent 5
Volla 5
Biên Hòa 4
Catania 4
Changsha 4
Columbus 4
Totale 3.541
Nome #
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 322
Cardiovascular risk in polycythemia vera: Thrombotic risk and survival: Can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? 283
CALR MUTATIONS IN SICILIAN ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS PATIENTS. 243
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 241
MOLECULAR ANALYSIS OF BRCA1/2 GENES AND MULTIGENE-PANEL TESTING IN SICILIAN TRIPLE NEGATIVE BREAST CANCER 237
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer 235
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 233
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 227
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 220
CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL 219
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 214
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 213
Multigene panel testing in Hereditary Breast and Ovarian Cancer: an effective liquid biopsy approach to identify mutations in genes involved in the Homologous Recombination pathway 210
COMPARISON OF CLINICAL AND LABORATORY DATA, INCLUDING JAK-2 46/1 HAPLOTYPE, BETWEEN PATIENTS WITH IDIOPATHIC ERYTHROCYTOSIS AND POLYCYTHEMIA VERA. 209
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 193
JAK2 ALLELE BURDEN IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS 192
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 187
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 181
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 174
HEREDITARY BREAST AND OVARIAN CANCER SYNDROME: FREQUENCY AND DISTRIBUTION OF BRCA1/2 PATHOGENIC VARIANTS IN SICILIAN POPULATION 170
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 164
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 160
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? 154
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 153
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study 150
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 143
BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants? 142
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 132
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints 128
Scientific Communication and oncology – "The bridge between knowledge and patients" 127
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors 125
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 124
null 25
Totale 6.130
Categoria #
all - tutte 20.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.262


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022225 0 0 9 18 8 24 10 23 28 34 23 48
2022/2023450 41 61 13 64 38 62 36 43 53 6 16 17
2023/2024341 13 31 22 36 28 63 62 14 7 12 8 45
2024/20251.185 36 51 61 58 56 88 190 112 73 152 157 151
2025/20262.898 262 123 178 256 285 498 433 248 232 170 110 103
2026/2027255 127 60 68 0 0 0 0 0 0 0 0 0
Totale 6.130